Tempest Therapeutics Reports Q1 Losses and Cash Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Should l Buy TPST?
Source: seekingalpha
- Financial Performance Decline: Tempest Therapeutics reported a Q1 GAAP EPS of -$2.53, an improvement from -$3.16 year-over-year, yet the net loss of $27.7 million indicates ongoing challenges in profitability.
- Cash Flow Strain: The company ended the quarter with only $1.8 million in cash and cash equivalents, a significant drop from $7.7 million on December 31, 2025, primarily due to one-time transaction costs associated with the asset acquisition, highlighting pressure on financial management.
- Financing Activities: Tempest Therapeutics is seeking up to $6 million in private placement to bolster liquidity, a move aimed at alleviating cash flow constraints and supporting future operational needs.
- Market Reaction: Despite showing signs of reduced losses in its financial report, investor concerns regarding ongoing cash flow issues may negatively impact stock prices, reflecting a cautious market sentiment towards the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TPST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TPST
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempest Therapeutics Reports Q1 Losses and Cash Decline
- Financial Performance Decline: Tempest Therapeutics reported a Q1 GAAP EPS of -$2.53, an improvement from -$3.16 year-over-year, yet the net loss of $27.7 million indicates ongoing challenges in profitability.
- Cash Flow Strain: The company ended the quarter with only $1.8 million in cash and cash equivalents, a significant drop from $7.7 million on December 31, 2025, primarily due to one-time transaction costs associated with the asset acquisition, highlighting pressure on financial management.
- Financing Activities: Tempest Therapeutics is seeking up to $6 million in private placement to bolster liquidity, a move aimed at alleviating cash flow constraints and supporting future operational needs.
- Market Reaction: Despite showing signs of reduced losses in its financial report, investor concerns regarding ongoing cash flow issues may negatively impact stock prices, reflecting a cautious market sentiment towards the company's future prospects.
See More
Tempest Therapeutics Reports FY Losses
- Disappointing Earnings: Tempest Therapeutics reported a FY GAAP EPS of -$6.33, missing expectations by $0.23, indicating ongoing challenges in profitability that may undermine investor confidence.
- Deteriorating Cash Position: As of December 31, 2024, Tempest's cash and cash equivalents dropped to $7.7 million from $30.3 million a year earlier, highlighting pressures in cash management and operational expenditures that could limit future R&D investments.
- Funding Initiative Launched: Tempest Therapeutics announced a private placement of up to $6 million aimed at improving liquidity and supporting R&D projects, although market confidence in its fundraising ability may be affected by the disappointing earnings report.
- Cautious Market Reaction: Following the earnings miss, the market is adopting a cautious stance towards Tempest's future prospects, leading investors to potentially reassess their strategies and resulting in increased stock price volatility.
See More
Insider Purchases of RPC and TPST Stocks
- RPC Insider Purchase: Ridgepost Capital Director David M. McCoy purchased 70,000 shares of RPC at $7.37 each on Monday, totaling an investment of $515,900, reflecting confidence in the company's future and contributing to a 3.1% increase in RPC's stock price on Thursday.
- TPST Stock Acquisition: Tempest Therapeutics CEO Matthew Angel bought 231,482 shares at $2.16 each on Tuesday, amounting to $500,001, despite the stock declining by 4.6% on Thursday, indicating executive recognition of the company's value.
- Market Reaction Analysis: Although Angel's purchase price exceeds the current market price of $1.65, which is 23.8% lower than his purchase price, investors can still enter at a lower price, reflecting differing views on TPST's short-term volatility versus long-term potential.
- Executive Confidence Indicator: Insider buying is often seen as a positive signal for a company's future performance, especially amid market fluctuations, prompting investors to pay attention to these signals for potential investment opportunities.
See More
Tempest Therapeutics Secures $6 Million Private Placement Financing
- Financing Agreement Details: Tempest Therapeutics announced a securities purchase agreement for a private placement of up to $6 million with participation from new and existing institutional investors, expected to close around March 23, 2026, with proceeds aimed at supporting clinical development and operational needs.
- Stock Issuance Terms: Under the agreement, Tempest will issue 925,927 shares of common stock along with Series A and short-term Series B warrants, priced at $2.16 per share, reflecting the company's current market conditions and investor interest.
- Clinical Program Progress: Tempest is advancing a portfolio of small-molecule and CAR-T candidates, with Amezalpat currently in a Phase 2 trial for hepatocellular carcinoma, indicating the company's commitment to addressing difficult-to-treat cancers.
- Stock Performance Volatility: Despite a 19.65% drop in TPST's stock price to $1.84 at Monday's close, the stock rebounded slightly to $1.88 in after-hours trading, suggesting mixed market reactions to the financing news.
See More
Tempest Therapeutics Announces Private Placement of Common Stock and Warrants
- Financing Size: Tempest Therapeutics announced a private placement involving 925,927 shares of common stock and corresponding Series A and short-term Series B warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Warrant Details: Both Series A and short-term Series B warrants have an exercise price of $2.16 per share and are expected to become exercisable upon shareholder approval, potentially generating an additional $4 million in proceeds if fully exercised, enhancing the company's financial flexibility.
- Use of Proceeds: The company intends to utilize the net proceeds from this offering for working capital and other general corporate purposes, demonstrating its focus on future business development and efficient capital utilization.
- Market Reaction: Following the financing announcement, Tempest Therapeutics' stock price fell 11.79% in pre-market trading to $2.02, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
See More
Tempest Selects Cincinnati Children's for Tech Transfer of TPST-2003
- Tech Transfer Partnership: Tempest Therapeutics has selected Cincinnati Children's Applied Gene and Cell Therapy Center as the lead contract development and manufacturing partner for TPST-2003, with all activities planned for completion by Q3 2026 to support a potential IND filing in Q4 2026, thereby accelerating the clinical development timeline for its CAR-T therapy.
- Clinical Trial Results: As of January 31, 2026, TPST-2003 has been administered to 36 patients with relapsed/refractory multiple myeloma, achieving a 100% complete response (CR) rate among the six efficacy evaluable patients, indicating strong efficacy in clinical trials and positioning the therapy as a potential class leader in the field.
- Market Potential: The dual-targeting design of TPST-2003 aims to improve response depth and durability, particularly for patients who have previously received BCMA-targeting CAR-T therapy, showcasing its unique advantages in treating relapsed/refractory multiple myeloma and potentially expanding treatment options for patients.
- Strategic Development: The collaboration with Cincinnati Children's not only enhances Tempest's technical capabilities in cell therapy but also lays the groundwork for future clinical development, expected to drive the IND application and subsequent market introduction of TPST-2003.
See More
Tempest Therapeutics Reports Q1 Losses and Cash Decline
- Financial Performance Decline: Tempest Therapeutics reported a Q1 GAAP EPS of -$2.53, an improvement from -$3.16 year-over-year, yet the net loss of $27.7 million indicates ongoing challenges in profitability.
- Cash Flow Strain: The company ended the quarter with only $1.8 million in cash and cash equivalents, a significant drop from $7.7 million on December 31, 2025, primarily due to one-time transaction costs associated with the asset acquisition, highlighting pressure on financial management.
- Financing Activities: Tempest Therapeutics is seeking up to $6 million in private placement to bolster liquidity, a move aimed at alleviating cash flow constraints and supporting future operational needs.
- Market Reaction: Despite showing signs of reduced losses in its financial report, investor concerns regarding ongoing cash flow issues may negatively impact stock prices, reflecting a cautious market sentiment towards the company's future prospects.
See More
Tempest Therapeutics Reports FY Losses
- Disappointing Earnings: Tempest Therapeutics reported a FY GAAP EPS of -$6.33, missing expectations by $0.23, indicating ongoing challenges in profitability that may undermine investor confidence.
- Deteriorating Cash Position: As of December 31, 2024, Tempest's cash and cash equivalents dropped to $7.7 million from $30.3 million a year earlier, highlighting pressures in cash management and operational expenditures that could limit future R&D investments.
- Funding Initiative Launched: Tempest Therapeutics announced a private placement of up to $6 million aimed at improving liquidity and supporting R&D projects, although market confidence in its fundraising ability may be affected by the disappointing earnings report.
- Cautious Market Reaction: Following the earnings miss, the market is adopting a cautious stance towards Tempest's future prospects, leading investors to potentially reassess their strategies and resulting in increased stock price volatility.
See More
Insider Purchases of RPC and TPST Stocks
- RPC Insider Purchase: Ridgepost Capital Director David M. McCoy purchased 70,000 shares of RPC at $7.37 each on Monday, totaling an investment of $515,900, reflecting confidence in the company's future and contributing to a 3.1% increase in RPC's stock price on Thursday.
- TPST Stock Acquisition: Tempest Therapeutics CEO Matthew Angel bought 231,482 shares at $2.16 each on Tuesday, amounting to $500,001, despite the stock declining by 4.6% on Thursday, indicating executive recognition of the company's value.
- Market Reaction Analysis: Although Angel's purchase price exceeds the current market price of $1.65, which is 23.8% lower than his purchase price, investors can still enter at a lower price, reflecting differing views on TPST's short-term volatility versus long-term potential.
- Executive Confidence Indicator: Insider buying is often seen as a positive signal for a company's future performance, especially amid market fluctuations, prompting investors to pay attention to these signals for potential investment opportunities.
See More
Tempest Therapeutics Secures $6 Million Private Placement Financing
- Financing Agreement Details: Tempest Therapeutics announced a securities purchase agreement for a private placement of up to $6 million with participation from new and existing institutional investors, expected to close around March 23, 2026, with proceeds aimed at supporting clinical development and operational needs.
- Stock Issuance Terms: Under the agreement, Tempest will issue 925,927 shares of common stock along with Series A and short-term Series B warrants, priced at $2.16 per share, reflecting the company's current market conditions and investor interest.
- Clinical Program Progress: Tempest is advancing a portfolio of small-molecule and CAR-T candidates, with Amezalpat currently in a Phase 2 trial for hepatocellular carcinoma, indicating the company's commitment to addressing difficult-to-treat cancers.
- Stock Performance Volatility: Despite a 19.65% drop in TPST's stock price to $1.84 at Monday's close, the stock rebounded slightly to $1.88 in after-hours trading, suggesting mixed market reactions to the financing news.
See More
Tempest Therapeutics Announces Private Placement of Common Stock and Warrants
- Financing Size: Tempest Therapeutics announced a private placement involving 925,927 shares of common stock and corresponding Series A and short-term Series B warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Warrant Details: Both Series A and short-term Series B warrants have an exercise price of $2.16 per share and are expected to become exercisable upon shareholder approval, potentially generating an additional $4 million in proceeds if fully exercised, enhancing the company's financial flexibility.
- Use of Proceeds: The company intends to utilize the net proceeds from this offering for working capital and other general corporate purposes, demonstrating its focus on future business development and efficient capital utilization.
- Market Reaction: Following the financing announcement, Tempest Therapeutics' stock price fell 11.79% in pre-market trading to $2.02, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
See More
Tempest Selects Cincinnati Children's for Tech Transfer of TPST-2003
- Tech Transfer Partnership: Tempest Therapeutics has selected Cincinnati Children's Applied Gene and Cell Therapy Center as the lead contract development and manufacturing partner for TPST-2003, with all activities planned for completion by Q3 2026 to support a potential IND filing in Q4 2026, thereby accelerating the clinical development timeline for its CAR-T therapy.
- Clinical Trial Results: As of January 31, 2026, TPST-2003 has been administered to 36 patients with relapsed/refractory multiple myeloma, achieving a 100% complete response (CR) rate among the six efficacy evaluable patients, indicating strong efficacy in clinical trials and positioning the therapy as a potential class leader in the field.
- Market Potential: The dual-targeting design of TPST-2003 aims to improve response depth and durability, particularly for patients who have previously received BCMA-targeting CAR-T therapy, showcasing its unique advantages in treating relapsed/refractory multiple myeloma and potentially expanding treatment options for patients.
- Strategic Development: The collaboration with Cincinnati Children's not only enhances Tempest's technical capabilities in cell therapy but also lays the groundwork for future clinical development, expected to drive the IND application and subsequent market introduction of TPST-2003.
See More
